Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (405)	3/9/2000 8:11:00 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 3557

Step forward; Thursday March 9, 9:17 am Eastern Time Company Press Release Regeneron and Emisphere to Collaborate on Oral Delivery of AXOKINE TARRYTOWN, N.Y.--(BUSINESS WIRE)--March 9, 2000--Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - news) announced that it has signed an agreement with Emisphere Technologies, Inc. (NASDAQ:EMIS - news) to establish a research and development collaboration to utilize Emisphere's oral drug delivery technology for Regeneron's AXOKINE© second generation ciliary neurotrophic factor. In preliminary preclinical pharmacokinetic studies, the Emisphere technology was able to achieve measurable blood levels of AXOKINE. Regeneron is developing AXOKINE for the treatment of obesity and complications of obesity such as Type II diabetes. Regeneron expects to start a Phase II dose-ranging trial to study the safety and efficacy of AXOKINE delivered subcutaneously (injection under the skin) by the end of March 2000. Under the terms of the agreement, Regeneron will support research at Emisphere and under certain conditions will make additional payments, including license and milestone payments. Regeneron will receive exclusive worldwide commercialization rights to oral products that result from the collaboration and pay Emisphere a royalty on sales of any such products. Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron's platform technologies include Targeted Genomics(TM), Functionomics(TM), and Designer Protein Therapeutics(TM). Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. This news release discusses historical information and includes forward looking statements about the collaboration between Regeneron and Emisphere and about their products, programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of drugs and biologics, determinations by regulatory and administrative governmental authorities, competitive factors, technological developments, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement to be canceled or to terminate without any product success, and other material risks. A more complete description of these risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ending December 31, 1999, a copy of which should be read before making any investment decision regarding Regeneron common stock. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information about Regeneron and recent news releases are available on Regeneron's Worldwide Web Home Page at www.regeneron.com. Fax copies of news releases can be obtained from Regeneron's News-on-Demand Service by dialing (800) 311-0841.